Pathophysiology, Diagnosis, and Management of Dyslipidemia

Current Problems in Cardiology

Volumn 31, Issue 7, 2006, Pages 445-486

  Gau, Gerald T ^a   Wright, R Scott ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANABOLIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DICYCLOVERINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINAMIDE; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOATING; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DYSLIPIDEMIA; FATIGUE; FLATULENCE; FOOD DRUG INTERACTION; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLUCURONIDATION; GOUT; GRAPEFRUIT JUICE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; LIVER METABOLISM; LIVER TOXICITY; MACROPHAGE; MESENTERIC ARTERY; METABOLIC SYNDROME X; MICROSURGERY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NEPHROSCLEROSIS; PAIN; PATHOPHYSIOLOGY; PATIENT CARE; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; RACE DIFFERENCE; RECURRENCE RISK; REVASCULARIZATION; RHABDOMYOLYSIS; RISK FACTOR; SECONDARY PREVENTION; SMOKING; STOMACH DISCOMFORT; STOMACH PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEAKNESS;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 33745638548     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2006.03.001     Document Type: Article

References (107)

1. Topol E. Intensive statin therapy-a sea change in cardiovascular prevention. New Engl J Med 350 (2004) 15
2. Wright R.S., Kottke T.E., and Gau G.T. Lipid-lowering Agents. In: Murphy J. (Ed). Mayo Clinic Cardiology Review. 2nd Ed. (2000), Lippincott Williams & Wilkins, Philadelphia, PA 1301-1318
3. Roberts W.C. The underused miracle drugs. the statin drugs are to atherosclerosis what penicillin was to infection disease. Am J Cardiol 78 (1996) 377-378
4. Grundy S.M., Cleeman J.L., Bairey Mertz N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
5. Kromhout D. On the waves of the Seven Countries Study. a public health perspective on cholesterol. Eur Heart J 20 (1999) 796-802
6. Vaughn C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 9034 (1996) 1079-1082
7. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 11 (1995) 2844-2850
8. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 92 5 (1995) 1355-1374
9. Fuster V. Mechanisms leading to myocardial infarction. insights from studies of vascular biology. Circulation 90 (1994) 2126-2146
10. Glass C.K., and Witztum J.L. Atherosclerosis. the road ahead. Cell 14 (2001) 503-516
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-III). JAMA 285 (2001) 2486-2497
12. Kromhout D. On the waves of the Seven Countries Study-a public health perspective on cholesterol. Eur Heart J 20 (1999) 796-802
13. Vaughn C.J., and Gotto A.M. Update on statins 2003. Circulation 110 (2004) 886-892
14. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
15. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease. the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
16. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and recurrent trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1000-1009
17. Long-term intervention with pravastatin in ischemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
18. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
19. Pedersen TR, Kjekshus J, Pyorala K, et al. Presented at American Heart Association Annual Meeting. Circulation 1995;92(8):1-672, abstract no. 3225.
20. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
21. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
22. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 8A (2002) 22i-29i
23. Omar M.A., Wilson J.P., and Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35 (2001) 1096-1107
24. Prueksaritanont T. Glucuronidation of statins in animals and humans. a novel mechanism of statin lactonization. Drug Metab Dispos 30 (2002) 505-512
25. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
26. Pastermak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106 (2002) 1024-1028
27. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1682-1690
28. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
29. Laaksonen R., Jokelainen K., Sahi T., et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 57 (1995) 62-66
30. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
31. Raskind J.Y., and El-Chaar G.M. The role of carnitine supplementation during valproic and therapy. Ann Pharmacother 34 (2003) 630-638
32. Ogasahara S., Engel A.G., Frens D., et al. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 86 (1989) 2379-2382
33. Coleman M.L., Olson M.F., and Rho G.T. Pase signaling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9 (2002) 493-504
34. Olson M.F., Ashworth A., and Hall A. An essential role for Rho, Rad, and Cdc42 GTPases in cell cycle progression through G1. Science 269 (1995) 1270-1272
35. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI Clinical Advisory on the use of safety of statins. Circulation (2002) 1024-1028
36. Moosmann B., and Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 363 (2004) 892-894
37. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials. prospective pravastatin pooling (PPP) project. Circulation 105 (2002) 2341-2346
38. Thompson P.D., Clarkson P., and Karas R.H. Stating-induced myopathy. JAMA 289 (2003) 1682-1690
39. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
40. Data file-personal communication and package insert data. AstraZeneca LP, Alderley Park, Macclesfield, Cheshire, UK; 1998-2003.
41. Jones P.H., Davidson M.H., Stein E.A., et al., STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 2 (2003) 152-160
42. Hunninghake D.B., Stein E.A., Bays H.E., et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 15 (2004) 115-123
43. Schneck D.W., Knopp R.H., Ballantyne C.M., et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 91 1 (2003) 33-41
44. Stein E.A., Strutt K., Southworth H., et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 92 (2003) 1287-1293
45. Berry D.A., Berry S.M., McKellar J., et al. Comparison of the dose-response relationships of two lipid-lowering agents. a Bayesian meta-analysis. Am Heart J 145 6 (2003) 1036-1045
46. The Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
47. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
48. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. a randomized controlled trial. JAMA 291 (2004) 1071-1080
49. Hsu I., Spinler S.A., and Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29 (1995) 743-759
50. Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151 (1991) 43-49
51. Pedersen T.R., and Tobert J.A. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. a reappraisal. Drug Saf 14 (1996) 11-24
52. Angelo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
53. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Am Soc Pharm Exp Ther 30 11 (2002) 1280-1287
54. Knopp R.H., Gitter H., Truitt T., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
55. Sudhop T., Lutjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
56. Gagne C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
57. Dujovne C.A., Ettinger M.P., and McNeer J.F. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, in ezetimibe, in patients with primary hypocholesterolemia. Am J Cardiol 90 (2002) 1092-1097
58. Davidson M.T., McGarry T., Bettis R., et al. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
59. Roberts W.C. Two more drugs for dyslipidemia. Am J Card 93 (2004) 809-811
60. Sager P.T., Melani L., Lipka L., et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity c-reactive protein. Am J Cardiol 92 (2003) 1414-1418
61. Zema MJ, Chan E. Ezetimibe and colesevelam are additive in the management of hypercholesterolemia. Presented at the American College of Chest Physicians meeting 2004, abstract.
62. Nguyen T.T., Dale L.C., vonBergmann K., et al. Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women. a randomized controlled trial. Mayo Clin Proc 74 12 (1999) 1198-1206
63. Brewer H.B. Increasing HDL cholesterol levels. N Engl J Med 350 (2004) 15 1491-4
64. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. N Engl J Med 350 15 (2004) 1505-1515
65. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant Apo A1 milano on coronary atherosclerosis in patients with acute coronary syndromes. a randomized controlled trial. JAMA 290 (2003) 2292-2300
66. Li D., Weng S., Yang B., et al. Inhibition of arterial thrombus formation by Apo A1 milano. Arterioscler Thromb Vasc Biol 19 (1999) 378-383
67. Bybee K.A., Wright R.S., Williams B.A., et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 87 (2001) 771-774
68. Schiefe R., Gitt A.K., Heer T., et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality. results of the Mitra-2. Circulation 102 (2000) II-435
69. Stenestrand U., and Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
70. Bybee K.A., Wright R.S., Powell B.D., et al. Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI. Circulation 102 suppl 2 (2000) II-614 [Abstract 2977]
71. Aronow H.D., Topol E.J., Roe M.T., et al. Effect of lipid lowering therapy on early mortality after acute coronary syndromes. an observational study. Lancet 357 (2001) 1063-1068
72. Giugliano R.P., Antman E.M., Thompson S.L., et al. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower post-discharge 1-year mortality. J Am Coll Cardiol 37 suppl A (2001) 316A [Abstract 1053-91]
73. Cannon C.P., McCabe C.H., Bentley J., et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes. observations from OPUS-TIMI 16. J Am Coll Cardiol 37 suppl A (2001) 334A [Abstract 831-2]
74. McGuire D.K., Kristinsson A., Bhapkar M.V., et al. Early statin use after acute coronary syndromes (ACS) and outcomes at 90 days. Circulation 104 (2001) II-343
75. Kayikcioglu M., Can L., Kultursay H., et al. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol 57 (2002) 295-302
76. Van Boven AJ, Liem A. Effects of fluvastatin administration immediately after an acute myocardial infarction on myocardial ischemia (FLORIDA). Presented at: American Heart Association Scientific Session 2000; November 12-15, 2000; New Orleans, LA. Available at: http://www.acc.org/education/online/trials/aha00/florida.htm
77. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the MIRACL study. JAMA 285 13 (2001) 1711-1718
78. Arntz H.R., Agrawal R., Wunderlich W., et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 86 (2000) 1293-1298
79. Wright R.S., Murphy J.G., Bybee K.A., et al. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina. efficacy and mechanism of benefit. Mayo Clin Proc 77 (2002) 1085-1092
80. Blazing M.A., de Lemos J.A., Dyke C.K., et al. The A-to-Z Trial. methods and rationale for a single trial investigating combined with use of a low-molecular-weight heparin with the glycoprotein IIb/III inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 142 (2001) 211-217
81. Ross A.M., Coyne K.S., Reiner J.S., et al., PACT investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction. the PACT trial. J Am Coll Cardiol 34 7 (1999) 1963-1965
82. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 292 11 (2004) 1307-1316
83. Fonarow G.C., French W.J., Parsons L.S., et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. data from the National Registry of Myocardial Infarction 3. Circulation 103 1 (2001) 38-44
84. Bybee K.A., Powell B.D., Williams B.A., et al. Superior short-term cholesterol control and achievement of the adult treatment panel III low-density lipoprotein goals with initiation of statin therapy by the time of hospital discharge following acute myocardial infarction. Am J Cardiol 93 (2004) 776-779
85. Rosenson R.S., and Tangey C.C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
86. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than lower cholesterol. Lancet 348 (1996) 1079-1082
87. Herrmann J., Lerman A., Baumgarat D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q wave myocardial infarction. Circulation 106 (2002) 2180-2183
88. Bybee K.A., Kopecky S.L., Williams B.A., et al. Reduced creatine kinase release with statin use at the time of myocardial infarction. Intl J Card 96 3 (2004) 461-466
89. Laufs U., La Fata V., Plutzky J., et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
90. Sever P.S., Dahlof B., Poulter N.R., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). a multicentre randomized controlled trial. Lancet 361 (2003) 1149-1158
91. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
92. Kim C., Gau G.T., and Allison T.G. Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease. Am J Cardiol 91 (2003) 1360-1363
93. Marcovina S.M., Koschinsky M.L., Albers J.J., et al. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein(a) and cardiovascular disease. recent advances and future directions. Clin Chem 49 (2003) 1785-1896
94. Deb A., and Caplice N. Lipoprotein A. New insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 27 (2004) 258-264
95. Bostrom L.A., Cupples J.L., Jenner L., et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger-a prospective study. JAMA 276 (1996) 544-548
96. van Wissen S., Smilde T.J., Trip M.D., et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 89 (2003) 893-896
97. Maher V.M., Brown B.G., Marcovina L.A., et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274 22 (1995) 1771-1774
98. Shlipak M.G., Simon J.A., Vittinghoff E., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283 (2000) 1845-1852
99. Gauthier G.M., Keevil J.G., and McBride P.E. The association of homocysteine and coronary artery disease. Clin Cardiol 26 (2003) 563-568
100. Wald D.S., Law M., and Morris J. Serum homocysteine and the severity of coronary artery disease. Thromb Res 111 (2003) 55-57
101. Matetzky S., Freimark D., Ben-Ami S., et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med 163 (2003) 1933-1937
102. Weisberg I.S., Park E., Ballman K.V., et al. Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis 167 (2003) 205-214
103. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
104. Ridker P.M., Rifai N., Pfeffer M.A., et al., The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 3 (1999) 230-235
105. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
106. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
107. Rubins H.B., Robins S.J., Collins J., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418